|
![]() |
|
|
Medroxyprogesterone
drug data and news
Medroxyprogesterone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Medroxyprogesterone | ||
| Brand Names/Synonyms | Amen; Aragest; Aragest 5; Asconale; CBP 1011; Clinofem; Clinovir; Colirest; Crinone; Curretab; Cycrin; DMPA; Depo-Clinovir; Depo-Prodasone; Depo-Progestin; Depo-Promone; Depo-Provera; Depo-Subq Provera 104; Depomedroxyprogesterone Acetate; Depot-Medroxyprogesterone Acetate; Farlutal; Farlutin; G-Farlutal; Gestapuran; HSDB 3114; Hematrol; Hydroxymethylprogesterone; Hysron; Indivina; Lunelle; Lutopolar; Lutoral; MAP; MPA; Med-Pro; Medroprogesterone Acetate; Medrossiprogesterone [Dcit]; Medroxiprogesterona [Inn-Spanish]; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteron Acetate; Medroxyprogesterone; Medroxyprogesterone Acetate; Medroxyprogesterone Base; Medroxyprogesteronum [Inn-Latin]; Meprate; Metigestrona; Mpa Gyn 5; Nadigest; Nidaxin; Novo-Medrone; Oragest; Perlutex; Perlutex Leo; Prempro/Premphase; Prodasone; Progestalfa; Progestasert; Progesterone; Progeston; Progevera; Prometrium; Provera; Proverone; Ralovera; Repromap; Repromix; Sirprogen; Sodelut G; U 8839; U 8840; Veramix | ||
| Indication | Contraception | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Medroxyprogesterone, a synthetic progestin more potent than progesterone, is used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions. | ||
| Mechanism Of Action | Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. | ||
| Medroxyprogesterone News (When available) |
Regulation of Monocyte Chemoattractant Protein-1 Expression by ... Feb 8, 2006 PRODUCT MARKETING NEWS Feb 21, 2006 New Data from Women's Health Initiative Study Show No Increased ... Feb 13, 2006 Women's Health Initiative Study Data Show No Increased Risk of ... Feb 14, 2006 Transvaginal Sonography of Hematotrachelos and Hematometra Causing ... Feb 9, 2006 FDA Sends Duramed Warning Letter Over Cenestin Ad Jan 18, 2006 Depot contraceptives boost weight in obese teens Jan 20, 2006 Depot contraceptives boost obese teens Jan 22, 2006 Some dangerous drugs get by FDA Jan 29, 2006 The North American Menopause Society Highlights from Jan/Feb Jan 12, 2006 Forkhead Transcription Factor FOXO1A is Critical for Induction of ... Jan 30, 2006 Obese Girls Using Depo Provera More Likely To Gain Weight, Study ... Jan 24, 2006 Consumer Reports Medical Guide & Consumer Reports: Prescription ... Dec 5, 2005 Dr. Bill Elliott: Hormone therapy may be best way to ease hot ... Nov 21, 2005 Unopposed Conjugated Equine Estrogens Don't Prevent Peripheral ... Nov 14, 2005 Menopause Society Postmenopausal Hormone Therapy and Breast Cancer ... Nov 17, 2005 Mechanisms of Abruption-Induced Premature Rupture of the Fetal ... Nov 8, 2005 Teva Reports Third Quarter 2005 Results Nov 8, 2005 FDA Approves ANGELIQ(R) to Treat Menopausal Moderate to Severe ... Oct 2, 2005 FDA Safety Labeling Changes: Camptosar, Keppra, Prempro/Premphase Sep 21, 2005 Estrogen Therapy May Not Increase Breast Cancer Recurrence Sep 20, 2005 Water In White House Press Room Contaminated! Sep 13, 2005 FDA Safety Labeling Changes: Emtriva, FazaClo, Climara/Climara Pro Sep 14, 2005 THROMBOSIS SECONDARY TO MEDROXYPROGESTERONE IN PATIENT AT RISK FOR ... Aug 31, 2005 FDA Safety Labeling Changes: Activella, Duramorph PF, Nutropin Sep 7, 2005 Castration not an answer for sex offenders Sep 2, 2005 Women Report Various Symptoms After Stopping Menopause Hormone ... Aug 25, 2005 Recurrent Vasomotor Symptoms Common for EPT Users in WHI After ... Aug 24, 2005 FDA Safety Labeling Changes: Arixtra and Alora Aug 10, 2005 Menopausal hormone therapy, women report various symptoms after ... Aug 4, 2005 Chemical castration ruled out for Fort Pierce man found guilty in ... Aug 3, 2005 Isopak announces spiral jet mill results Aug 1, 2005 Women Report Various Symptoms After Stopping Hormone Therapy Jul 12, 2005 The Cochrane Library newsletter, 2005, issue 3 Jul 19, 2005 Stopping menopausal therapy revives symptoms in women Jul 13, 2005 Women Experience Symptoms After Stopping Hormone Therapy Jul 12, 2005 This Week in JAMA Jul 12, 2005 Partner Violence, Memory and Lung Cancer - Women's Health Research ... Jul 9, 2005 Note to Tom Cruise: It's My Hormones, Stupid! Jul 9, 2005 Woman sues companies over cancer Jul 14, 2005 Lack of grooming can signal health problem Jul 16, 2005 | ||
| Dosage Forms | Oral tablets, and Depo injection | ||
| Drug_Category | Contraceptives; Progestins; ATC:G03AC06; ATC:G03DA02; ATC:L02AB02 | ||
| Absorption | Rapidly absorbed from GI tract | ||
| Interactions |
-->Interactions for Medroxyprogesterone: No drug-drug interaction studies have been conducted with depo-subQ provera 104. Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. Laboratory Tests The pathologist should be advised of progestin therapy when relevant specimens are submitted. The physician should be informed that certain endocrine and liver function tests, and blood components may be affected by progestin therapy: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (b) Plasma and urinary gonadotropin levels are decreased (e.g., LH, FSH). (c) SHBG concentrations are decreased. (d) T3-uptake values may decrease. (e) There may be small changes in coagulation factors. (f) Sulfobromophthalein and other liver function test values may be increased slightly. (g) There may be small changes in lipid profiles. | ||
| Toxicity | Loss of Bone Mineral Density, BMD Changes in Adult Women, Bleeding Irregularities, Cancer Risks, Thromboembolic Disorders, LD50=mg/kg (orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 17-acetyl-17-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one | ||
| Chemical Formula | C22H32O3 | ||
| Molecular Weight | 344.488 g/mol | ||
| Smiles String | CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C | ||
| Melting Point | 220 - 223.5 °C | ||
| Water Solubility | 22.2mg/L | ||
| State | white to off-white, odorless crystalline powder | ||
| LogP/Hphobicity | 3.606 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 50 days | ||
| Protein Binding [%] | 90% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Medroxyprogesterone.html http://www.rxlist.com/cgi/generic/medrox.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00627 | ||
| CAS Registry Number | 520-85-4 | ||
| KEGG Compound ID | C07119 | ||
| PubChem ID | SID:9330 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2247583 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |